Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

David Crittenden Hooper, M.D.

TitleProfessor of Medicine
InstitutionMassachusetts General Hospital
DepartmentMedicine
AddressMassachusetts General Hospital
Infectious Disease
55 Fruit St
Boston MA 02114
Phone617/726-3812
Fax617/726-7416

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Jacoby GA, Hooper DC. Phylogenetic analysis of chromosomally determined qnr and related proteins. Antimicrob Agents Chemother. 2013 Apr; 57(4):1930-4.
    View in: PubMed
  2. Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, Billig M, Riddell K, Rogers P, Qin X, Butler-Wu S, Price LB, Aziz M, Nicolas-Chanoine MH, Debroy C, Robicsek A, Hansen G, Urban C, Platell J, Trott DJ, Zhanel G, Weissman SJ, Cookson BT, Fang FC, Limaye AP, Scholes D, Chattopadhyay S, Hooper DC, Sokurenko EV. Abrupt Emergence of a Single Dominant Multidrug-Resistant Strain of Escherichia coli. J Infect Dis. 2013 Mar; 207(6):919-28.
    View in: PubMed
  3. Shenoy ES, Hsu H, Noubary F, Hooper DC, Walensky RP. National Survey of Infection Preventionists: Policies for Discontinuation of Contact Precautions for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus. Infect Control Hosp Epidemiol. 2012 Dec; 33(12):1272-5.
    View in: PubMed
  4. Ding Y, Fu Y, Lee JC, Hooper DC. Staphylococcus aureus NorD, a Putative Efflux Pump Coregulated with the Opp1 Oligopeptide Permease, Contributes Selectively to Fitness In Vivo. J Bacteriol. 2012 Dec; 194(23):6586-93.
    View in: PubMed
  5. Shenoy ES, Walensky RP, Lee H, Orcutt B, Hooper DC. Resource burden associated with contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: the patient access managers' perspective. Infect Control Hosp Epidemiol. 2012 Aug; 33(8):849-52.
    View in: PubMed
  6. Yokoe DS, Khan Y, Olsen MA, Hooper DC, Greenbaum M, Vostok J, Lankiewicz J, Fraser VJ, Stevenson KB. Enhanced surgical site infection surveillance following hysterectomy, vascular, and colorectal surgery. Infect Control Hosp Epidemiol. 2012 Aug; 33(8):768-73.
    View in: PubMed
  7. Hooper DC, DeMaria A, Limbago BM, O'Brien TF, McCaughey B. Antibiotic resistance: how serious is the problem, and what can be done? Clin Chem. 2012 Aug; 58(8):1182-6.
    View in: PubMed
  8. Qualls ML, Mooney MM, Camargo CA, Zucconi T, Hooper DC, Pallin DJ. Emergency department visit rates for abscess versus other skin infections during the emergence of community-associated methicillin-resistant Staphylococcus aureus, 1997-2007. Clin Infect Dis. 2012 Jul; 55(1):103-5.
    View in: PubMed
  9. Bogoch II, Davis BT, Hooper DC. Severe babesiosis in a patient treated with a tumor necrosis factor a antagonist. Clin Infect Dis. 2012 Apr; 54(8):1215-6.
    View in: PubMed
  10. Truong-Bolduc QC, Hsing LC, Villet R, Bolduc GR, Estabrooks Z, Taguezem GF, Hooper DC. Reduced aeration affects the expression of the NorB efflux pump of Staphylococcus aureus by posttranslational modification of MgrA. J Bacteriol. 2012 Apr; 194(7):1823-34.
    View in: PubMed
  11. Lankiewicz JD, Yokoe DS, Olsen MA, Onufrak F, Fraser VJ, Stevenson K, Khan Y, Hooper D, Platt R, Huang SS. Beyond 30 days: does limiting the duration of surgical site infection follow-up limit detection? Infect Control Hosp Epidemiol. 2012 Feb; 33(2):202-4.
    View in: PubMed
  12. Calderwood MS, Ma A, Khan YM, Olsen MA, Bratzler DW, Yokoe DS, Hooper DC, Stevenson K, Fraser VJ, Platt R, Huang SS. Use of Medicare diagnosis and procedure codes to improve detection of surgical site infections following hip arthroplasty, knee arthroplasty, and vascular surgery. Infect Control Hosp Epidemiol. 2012 Jan; 33(1):40-9.
    View in: PubMed
  13. Okumura R, Liao CH, Gavin M, Jacoby GA, Hooper DC. Quinolone induction of qnrVS1 in Vibrio splendidus and plasmid-carried qnrS1 in Escherichia coli, a mechanism independent of the SOS system. Antimicrob Agents Chemother. 2011 Dec; 55(12):5942-5.
    View in: PubMed
  14. Truong-Bolduc QC, Dunman PM, Eidem T, Hooper DC. Transcriptional profiling analysis of the global regulator NorG, a GntR-like protein of Staphylococcus aureus. J Bacteriol. 2011 Nov; 193(22):6207-14.
    View in: PubMed
  15. Jacoby GA, Griffin CM, Hooper DC. Citrobacter spp. as a source of qnrB Alleles. Antimicrob Agents Chemother. 2011 Nov; 55(11):4979-84.
    View in: PubMed
  16. Huang SS, Placzek H, Livingston J, Ma A, Onufrak F, Lankiewicz J, Kleinman K, Bratzler D, Olsen MA, Lyles R, Khan Y, Wright P, Yokoe DS, Fraser VJ, Weinstein RA, Stevenson K, Hooper D, Vostok J, Datta R, Nsa W, Platt R. Use of Medicare claims to rank hospitals by surgical site infection risk following coronary artery bypass graft surgery. Infect Control Hosp Epidemiol. 2011 Aug; 32(8):775-83.
    View in: PubMed
  17. Vetting MW, Hegde SS, Wang M, Jacoby GA, Hooper DC, Blanchard JS. Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance factor. J Biol Chem. 2011 Jul 15; 286(28):25265-73.
    View in: PubMed
  18. Truong-Bolduc QC, Bolduc GR, Okumura R, Celino B, Bevis J, Liao CH, Hooper DC. Implication of the NorB efflux pump in the adaptation of Staphylococcus aureus to growth at acid pH and in resistance to moxifloxacin. Antimicrob Agents Chemother. 2011 Jul; 55(7):3214-9.
    View in: PubMed
  19. Didier JP, Villet R, Huggler E, Lew DP, Hooper DC, Kelley WL, Vaudaux P. Impact of ciprofloxacin exposure on Staphylococcus aureus genomic alterations linked with emergence of rifampin resistance. Antimicrob Agents Chemother. 2011 May; 55(5):1946-52.
    View in: PubMed
  20. Kim HB, Park CH, Gavin M, Jacoby GA, Hooper DC. Cold shock induces qnrA expression in Shewanella algae. Antimicrob Agents Chemother. 2011 Jan; 55(1):414-6.
    View in: PubMed
  21. Hyle EP, Ferraro MJ, Silver M, Lee H, Hooper DC. Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes. Infect Control Hosp Epidemiol. 2010 Dec; 31(12):1242-9.
    View in: PubMed
  22. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010 May 13; 362(19):1804-13.
    View in: PubMed
  23. Truong-Bolduc QC, Hooper DC. Phosphorylation of MgrA and its effect on expression of the NorA and NorB efflux pumps of Staphylococcus aureus. J Bacteriol. 2010 May; 192(10):2525-34.
    View in: PubMed
  24. Kim HB, Wang M, Ahmed S, Park CH, LaRocque RC, Faruque AS, Salam MA, Khan WA, Qadri F, Calderwood SB, Jacoby GA, Hooper DC. Transferable quinolone resistance in Vibrio cholerae. Antimicrob Agents Chemother. 2010 Feb; 54(2):799-803.
    View in: PubMed
  25. Hooper DC, Phares TW, Fabis MJ, Roy A. The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system. PLoS Negl Trop Dis. 2009; 3(10):e535.
    View in: PubMed
  26. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev. 2009 Oct; 22(4):664-89.
    View in: PubMed
  27. Pallin DJ, Espinola JA, Leung DY, Hooper DC, Camargo CA. Epidemiology of dermatitis and skin infections in United States physicians' offices, 1993-2005. Clin Infect Dis. 2009 Sep 15; 49(6):901-7.
    View in: PubMed
  28. Kim HB, Wang M, Park CH, Kim EC, Jacoby GA, Hooper DC. oqxAB encoding a multidrug efflux pump in human clinical isolates of Enterobacteriaceae. Antimicrob Agents Chemother. 2009 Aug; 53(8):3582-4.
    View in: PubMed
  29. Bolon MK, Hooper D, Stevenson KB, Greenbaum M, Olsen MA, Herwaldt L, Noskin GA, Fraser VJ, Climo M, Khan Y, Vostok J, Yokoe DS. Improved surveillance for surgical site infections after orthopedic implantation procedures: extending applications for automated data. Clin Infect Dis. 2009 May 1; 48(9):1223-9.
    View in: PubMed
  30. Wang M, Guo Q, Xu X, Wang X, Ye X, Wu S, Hooper DC, Wang M. New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother. 2009 May; 53(5):1892-7.
    View in: PubMed
  31. Jacoby GA, Gacharna N, Black TA, Miller GH, Hooper DC. Temporal appearance of plasmid-mediated quinolone resistance genes. Antimicrob Agents Chemother. 2009 Apr; 53(4):1665-6.
    View in: PubMed
  32. Kim HB, Park CH, Kim CJ, Kim EC, Jacoby GA, Hooper DC. Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother. 2009 Feb; 53(2):639-45.
    View in: PubMed
  33. Wang M, Jacoby GA, Mills DM, Hooper DC. SOS regulation of qnrB expression. Antimicrob Agents Chemother. 2009 Feb; 53(2):821-3.
    View in: PubMed
  34. Truong-Bolduc QC, Ding Y, Hooper DC. Posttranslational modification influences the effects of MgrA on norA expression in Staphylococcus aureus. J Bacteriol. 2008 Nov; 190(22):7375-81.
    View in: PubMed
  35. Ding Y, Onodera Y, Lee JC, Hooper DC. NorB, an efflux pump in Staphylococcus aureus strain MW2, contributes to bacterial fitness in abscesses. J Bacteriol. 2008 Nov; 190(21):7123-9.
    View in: PubMed
  36. Vetting MW, Park CH, Hegde SS, Jacoby GA, Hooper DC, Blanchard JS. Mechanistic and structural analysis of aminoglycoside N-acetyltransferase AAC(6')-Ib and its bifunctional, fluoroquinolone-active AAC(6')-Ib-cr variant. Biochemistry. 2008 Sep 16; 47(37):9825-35.
    View in: PubMed
  37. Jacoby G, Cattoir V, Hooper D, Martínez-Martínez L, Nordmann P, Pascual A, Poirel L, Wang M. qnr Gene nomenclature. Antimicrob Agents Chemother. 2008 Jul; 52(7):2297-9.
    View in: PubMed
  38. Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008 Mar; 51(3):291-8.
    View in: PubMed
  39. Fabis MJ, Scott GS, Kean RB, Koprowski H, Hooper DC. Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models. Proc Natl Acad Sci U S A. 2007 Mar 27; 104(13):5656-61.
    View in: PubMed
  40. Truong-Bolduc QC, Hooper DC. The transcriptional regulators NorG and MgrA modulate resistance to both quinolones and beta-lactams in Staphylococcus aureus. J Bacteriol. 2007 Apr; 189(8):2996-3005.
    View in: PubMed
  41. Bhattacharyya T, Hooper DC. Antibiotic dosing before primary hip and knee replacement as a pay-for-performance measure. J Bone Joint Surg Am. 2007 Feb; 89(2):287-91.
    View in: PubMed
  42. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006 Oct; 6(10):629-40.
    View in: PubMed
  43. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother. 2006 Nov; 50(11):3953-5.
    View in: PubMed
  44. Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother. 2006 Aug; 50(8):2872-4.
    View in: PubMed
  45. Gay K, Robicsek A, Strahilevitz J, Park CH, Jacoby G, Barrett TJ, Medalla F, Chiller TM, Hooper DC. Plasmid-mediated quinolone resistance in non-Typhi serotypes of Salmonella enterica. Clin Infect Dis. 2006 Aug 1; 43(3):297-304.
    View in: PubMed
  46. Jacoby GA, Walsh KE, Mills DM, Walker VJ, Oh H, Robicsek A, Hooper DC. qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob Agents Chemother. 2006 Apr; 50(4):1178-82.
    View in: PubMed
  47. Truong-Bolduc QC, Strahilevitz J, Hooper DC. NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob Agents Chemother. 2006 Mar; 50(3):1104-7.
    View in: PubMed
  48. Strahilevitz J, Robicsek A, Hooper DC. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones. Antimicrob Agents Chemother. 2006 Feb; 50(2):600-6.
    View in: PubMed
  49. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 2006 Jan; 12(1):83-8.
    View in: PubMed
  50. Strahilevitz J, Truong-Bolduc QC, Hooper DC. DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases. Antimicrob Agents Chemother. 2005 Dec; 49(12):5051-7.
    View in: PubMed
  51. Strahilevitz J, Onodera Y, Hooper DC. An improved expression plasmid for affinity purification of Staphylococcus aureus gyrase A subunit. Protein Expr Purif. 2006 May; 47(1):10-5.
    View in: PubMed
  52. de Souza NJ, Gupte SV, Deshpande PK, Desai VN, Bhawsar SB, Yeole RD, Shukla MC, Strahilevitz J, Hooper DC, Bozdogan B, Appelbaum PC, Jacobs MR, Shetty N, Patel MV, Jha R, Khorakiwala HF. A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. J Med Chem. 2005 Aug 11; 48(16):5232-42.
    View in: PubMed
  53. Varghese JC, Hahn PF, Harisinghani MG, Hayat SM, Gervais DA, Hooper DC, Mueller PR. Fungus-infected fluid collections in thorax or abdomen: effectiveness of percutaneous catheter drainage. Radiology. 2005 Aug; 236(2):730-8.
    View in: PubMed
  54. Robicsek A, Sahm DF, Strahilevitz J, Jacoby GA, Hooper DC. Broader distribution of plasmid-mediated quinolone resistance in the United States. Antimicrob Agents Chemother. 2005 Jul; 49(7):3001-3.
    View in: PubMed
  55. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob Agents Chemother. 2005 Jul; 49(7):3050-2.
    View in: PubMed
  56. Hooper DC. Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists. Clin Infect Dis. 2005 Jun 15; 40(12):1811-7.
    View in: PubMed
  57. Strahilevitz J, Hooper DC. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother. 2005 May; 49(5):1949-56.
    View in: PubMed
  58. Truong-Bolduc QC, Dunman PM, Strahilevitz J, Projan SJ, Hooper DC. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol. 2005 Apr; 187(7):2395-405.
    View in: PubMed
  59. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother. 2005 Jan; 49(1):118-25.
    View in: PubMed
  60. Yokoe DS, Noskin GA, Cunnigham SM, Zuccotti G, Plaskett T, Fraser VJ, Olsen MA, Tokars JI, Solomon S, Perl TM, Cosgrove SE, Tilson RS, Greenbaum M, Hooper DC, Sands KE, Tully J, Herwaldt La, Diekema DJ, Wong ES, Climo M, Platt R. Enhanced identification of postoperative infections among inpatients. Emerg Infect Dis. 2004 Nov; 10(11):1924-30.
    View in: PubMed
  61. Ellerin TB, Walsh SR, Hooper DC. Recurrent meningitis of unknown aetiology. Lancet. 2004 May 29; 363(9423):1772.
    View in: PubMed
  62. Wang M, Sahm DF, Jacoby GA, Zhang Y, Hooper DC. Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr. Antimicrob Agents Chemother. 2004 Apr; 48(4):1400-1.
    View in: PubMed
  63. Wang M, Sahm DF, Jacoby GA, Hooper DC. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother. 2004 Apr; 48(4):1295-9.
    View in: PubMed
  64. Bisognano C, Kelley WL, Estoppey T, Francois P, Schrenzel J, Li D, Lew DP, Hooper DC, Cheung AL, Vaudaux P. A recA-LexA-dependent pathway mediates ciprofloxacin-induced fibronectin binding in Staphylococcus aureus. J Biol Chem. 2004 Mar 5; 279(10):9064-71.
    View in: PubMed
  65. Ince D, Hooper DC. Quinolone resistance due to reduced target enzyme expression. J Bacteriol. 2003 Dec; 185(23):6883-92.
    View in: PubMed
  66. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis. 2003 Nov; 9(11):1415-22.
    View in: PubMed
  67. Sands KE, Yokoe DS, Hooper DC, Tully JL, Horan TC, Gaynes RP, Solomon SL, Platt R. Detection of postoperative surgical-site infections: comparison of health plan-based surveillance with hospital-based programs. Infect Control Hosp Epidemiol. 2003 Oct; 24(10):741-3.
    View in: PubMed
  68. Wang M, Tran JH, Jacoby GA, Zhang Y, Wang F, Hooper DC. Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother. 2003 Jul; 47(7):2242-8.
    View in: PubMed
  69. Truong-Bolduc QC, Zhang X, Hooper DC. Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J Bacteriol. 2003 May; 185(10):3127-38.
    View in: PubMed
  70. Ince D, Zhang X, Hooper DC. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother. 2003 Apr; 47(4):1410-5.
    View in: PubMed
  71. Ince D, Zhang X, Silver LC, Hooper DC. Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother. 2003 Jan; 47(1):274-82.
    View in: PubMed
  72. Ince D, Zhang X, Silver LC, Hooper DC. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother. 2002 Nov; 46(11):3370-80.
    View in: PubMed
  73. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis. 2002 Sep; 2(9):530-8.
    View in: PubMed
  74. Mandell LA, Peterson LR, Wise R, Hooper D, Low DE, Schaad UB, Klugman KP, Courvalin P. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis. 2002 Sep 15; 35(6):721-7.
    View in: PubMed
  75. Yu JL, Grinius L, Hooper DC. NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. J Bacteriol. 2002 Mar; 184(5):1370-7.
    View in: PubMed
  76. Lawrence LE, Frosco M, Ryan B, Chaniewski S, Yang H, Hooper DC, Barrett JF. Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations. Antimicrob Agents Chemother. 2002 Jan; 46(1):191-5.
    View in: PubMed
  77. Ince D, Hooper DC. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother. 2001 Oct; 45(10):2755-64.
    View in: PubMed
  78. Hooper DC. Minimizing potential resistance: the molecular view--a comment on Courvalin and Trieu-Cuot. Clin Infect Dis. 2001 Sep 15; 33 Suppl 3:S157-60.
    View in: PubMed
  79. Zachary KC, Bayne PS, Morrison VJ, Ford DS, Silver LC, Hooper DC. Contamination of gowns, gloves, and stethoscopes with vancomycin-resistant enterococci. Infect Control Hosp Epidemiol. 2001 Sep; 22(9):560-4.
    View in: PubMed
  80. Fournier B, Truong-Bolduc QC, Zhang X, Hooper DC. A mutation in the 5' untranslated region increases stability of norA mRNA, encoding a multidrug resistance transporter of Staphylococcus aureus. J Bacteriol. 2001 Apr; 183(7):2367-71.
    View in: PubMed
  81. Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis. 2001 Mar 15; 32 Suppl 1:S9-S15.
    View in: PubMed
  82. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001 Mar-Apr; 7(2):337-41.
    View in: PubMed
  83. Nigri GR, Tsai S, Kossodo S, Waterman P, Fungaloi P, Hooper DC, Doukas AG, LaMuraglia GM. Laser-induced shock waves enhance sterilization of infected vascular prosthetic grafts. Lasers Surg Med. 2001; 29(5):448-54.
    View in: PubMed
  84. Ince D, Hooper DC. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob Agents Chemother. 2000 Dec; 44(12):3344-50.
    View in: PubMed
  85. Catalano OA, Hahn PF, Hooper DC, Mueller PR. Efficacy of percutaneous abscess drainage in patients with vancomycin-resistant enterococci. AJR Am J Roentgenol. 2000 Aug; 175(2):533-6.
    View in: PubMed
  86. Fournier B, Zhao X, Lu T, Drlica K, Hooper DC. Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob Agents Chemother. 2000 Aug; 44(8):2160-5.
    View in: PubMed
  87. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 2000 Aug; 31 Suppl 2:S24-8.
    View in: PubMed
  88. Fournier B, Hooper DC. A new two-component regulatory system involved in adhesion, autolysis, and extracellular proteolytic activity of Staphylococcus aureus. J Bacteriol. 2000 Jul; 182(14):3955-64.
    View in: PubMed
  89. Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis. 2000 Feb; 30(2):243-54.
    View in: PubMed
  90. Fournier B, Aras R, Hooper DC. Expression of the multidrug resistance transporter NorA from Staphylococcus aureus is modified by a two-component regulatory system. J Bacteriol. 2000 Feb; 182(3):664-71.
    View in: PubMed
  91. Hooper DC. The fluoroquinolones after ciprofloxacin and ofloxacin. Curr Clin Top Infect Dis. 2000; 20:63-91.
    View in: PubMed
  92. Fournier B, Gravel A, Hooper DC, Roy PH. Strength and regulation of the different promoters for chromosomal beta-lactamases of Klebsiella oxytoca. Antimicrob Agents Chemother. 1999 Apr; 43(4):850-5.
    View in: PubMed
  93. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat. 1999 Feb; 2(1):38-55.
    View in: PubMed
  94. Hooper DC. Mode of action of fluoroquinolones. Drugs. 1999; 58 Suppl 2:6-10.
    View in: PubMed
  95. Hooper DC. Clinical applications of quinolones. Biochim Biophys Acta. 1998 Oct 1; 1400(1-3):45-61.
    View in: PubMed
  96. Hooper DC. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin Infect Dis. 1998 Aug; 27 Suppl 1:S54-63.
    View in: PubMed
  97. Fournier B, Hooper DC. Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity. Antimicrob Agents Chemother. 1998 Aug; 42(8):2109-12.
    View in: PubMed
  98. Ng EW, Samiy N, Ruoff KL, Cousins FV, Hooper DC, von Gunten S, D'Amico DJ, Baker AS. Treatment of experimental Staphylococcus epidermidis endophthalmitis with oral trovafloxacin. Am J Ophthalmol. 1998 Aug; 126(2):278-87.
    View in: PubMed
  99. Kontoyiannis DP, Ruoff K, Hooper DC. Nocardia bacteremia. Report of 4 cases and review of the literature. Medicine (Baltimore). 1998 Jul; 77(4):255-67.
    View in: PubMed
  100. Fridkin SK, Yokoe DS, Whitney CG, Onderdonk A, Hooper DC. Epidemiology of a dominant clonal strain of vancomycin-resistant Enterococcus faecium at separate hospitals in Boston, Massachusetts. J Clin Microbiol. 1998 Apr; 36(4):965-70.
    View in: PubMed
  101. Hooper DC. Structure of grepafloxacin relative to activity and safety profile. Clin Microbiol Infect. 1998 Mar; 4 Suppl 1:S15-S20.
    View in: PubMed
  102. Fournier B, Hooper DC. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrob Agents Chemother. 1998 Jan; 42(1):121-8.
    View in: PubMed
  103. Pegues DA, Colby C, Hibberd PL, Cohen LG, Ausubel FM, Calderwood SB, Hooper DC. The epidemiology of resistance to ofloxacin and oxacillin among clinical coagulase-negative staphylococcal isolates: analysis of risk factors and strain types. Clin Infect Dis. 1998 Jan; 26(1):72-9.
    View in: PubMed
  104. Pegues DA, Pegues CF, Hibberd PL, Ford DS, Hooper DC. Emergence and dissemination of a highly vancomycin-resistant vanA strain of Enterococcus faecium at a large teaching hospital. J Clin Microbiol. 1997 Jun; 35(6):1565-70.
    View in: PubMed
  105. Breines DM, Ouabdesselam S, Ng EY, Tankovic J, Shah S, Soussy CJ, Hooper DC. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother. 1997 Jan; 41(1):175-9.
    View in: PubMed
  106. Threlkeld SC, Hooper DC. Update on management of patients with Nocardia infection. Curr Clin Top Infect Dis. 1997; 17:1-23.
    View in: PubMed
  107. Ng EY, Trucksis M, Hooper DC. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother. 1996 Aug; 40(8):1881-8.
    View in: PubMed
  108. Pegues CF, Pegues DA, Ford DS, Hibberd PL, Carson LA, Raine CM, Hooper DC. Burkholderia cepacia respiratory tract acquisition: epidemiology and molecular characterization of a large nosocomial outbreak. Epidemiol Infect. 1996 Jun; 116(3):309-17.
    View in: PubMed
  109. Chen NT, Butler PE, Hooper DC, May JW. Bacterial growth in saline implants: in vitro and in vivo studies. Ann Plast Surg. 1996 Apr; 36(4):337-41.
    View in: PubMed
  110. Hooper DC. From fluoroquinolones to 2-pyridones. Lancet. 1995 May 13; 345(8959):1192-3.
    View in: PubMed
  111. Hooper DC. Quinolone mode of action. Drugs. 1995; 49 Suppl 2:10-5.
    View in: PubMed
  112. Hooper DC. Bacterial resistance to fluoroquinolones: mechanisms and patterns. Adv Exp Med Biol. 1995; 390:49-57.
    View in: PubMed
  113. Ng EY, Trucksis M, Hooper DC. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother. 1994 Jun; 38(6):1345-55.
    View in: PubMed
  114. Chen NT, Hong HZ, Hooper DC, May JW. The effect of systemic antibiotic and antibiotic-impregnated polymethylmethacrylate beads on the bacterial clearance in wounds containing contaminated dead bone. Plast Reconstr Surg. 1993 Dec; 92(7):1305-11; discussion 1312-3.
    View in: PubMed
  115. Hooper DC. Quinolone mode of action--new aspects. Drugs. 1993; 45 Suppl 3:8-14.
    View in: PubMed
  116. Hooper DC, Wolfson JS, Bozza MA, Ng EY. Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB. Antimicrob Agents Chemother. 1992 May; 36(5):1151-4.
    View in: PubMed
  117. Wolfson JS, Hooper DC. Overview of fluoroquinolone safety. Am J Med. 1991 Dec 30; 91(6A):153S-161S.
    View in: PubMed
  118. Trucksis M, Wolfson JS, Hooper DC. A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J Bacteriol. 1991 Sep; 173(18):5854-60.
    View in: PubMed
  119. Wolfson JS, Hooper DC. Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microbiol Infect Dis. 1991 Apr; 10(4):267-74.
    View in: PubMed
  120. Hooper DC, Wolfson JS. Mode of action of the new quinolones: new data. Eur J Clin Microbiol Infect Dis. 1991 Apr; 10(4):223-31.
    View in: PubMed
  121. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991 Feb 7; 324(6):384-94.
    View in: PubMed
  122. Wolfson JS, Hooper DC, McHugh GL, Bozza MA, Swartz MN. Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents. Antimicrob Agents Chemother. 1990 Oct; 34(10):1938-43.
    View in: PubMed
  123. Masem M, Greenberg BM, Hoffman C, Hooper DC, May JW. Comparative bacterial clearances of muscle and skin/subcutaneous tissues with and without dead bone: a laboratory study. Plast Reconstr Surg. 1990 May; 85(5):773-81.
    View in: PubMed
  124. Hooper DC, Wolfson JS. Bacterial resistance to the quinolone antimicrobial agents. Am J Med. 1989 Dec 29; 87(6C):17S-23S.
    View in: PubMed
  125. Wolfson JS, Hooper DC. Comparative pharmacokinetics of ofloxacin and ciprofloxacin. Am J Med. 1989 Dec 29; 87(6C):31S-36S.
    View in: PubMed
  126. Hooper DC, Wolfson JS. Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects. Antimicrob Agents Chemother. 1989 Oct; 33(10):1662-7.
    View in: PubMed
  127. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct; 2(4):378-424.
    View in: PubMed
  128. Wolfson JS, Hooper DC. Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis. Antimicrob Agents Chemother. 1989 Oct; 33(10):1655-61.
    View in: PubMed
  129. Wolfson JS, Hooper DC. Bacterial resistance to quinolones: mechanisms and clinical importance. Rev Infect Dis. 1989 Jul-Aug; 11 Suppl 5:S960-8.
    View in: PubMed
  130. Hooper DC, Wolfson JS. Mode of action of the quinolone antimicrobial agents: review of recent information. Rev Infect Dis. 1989 Jul-Aug; 11 Suppl 5:S902-11.
    View in: PubMed
  131. Wolfson JS, Hooper DC, Shih DJ, McHugh GL, Swartz MN. Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones. Antimicrob Agents Chemother. 1989 May; 33(5):705-9.
    View in: PubMed
  132. Hooper DC, Wolfson JS, Tung C, Souza KS, Swartz MN. Effects of inhibition of the B subunit of DNA gyrase on conjugation in Escherichia coli. J Bacteriol. 1989 Apr; 171(4):2235-7.
    View in: PubMed
  133. Hooper DC, Wolfson JS, Souza KS, Ng EY, McHugh GL, Swartz MN. Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob Agents Chemother. 1989 Mar; 33(3):283-90.
    View in: PubMed
  134. Kerschmann RL, Wolfson JS, McHugh GL, Dickersin GR, Hooper DC, Swartz MN. Novobiocin-induced ultrastructural changes and antagonism of DNA synthesis in Trypanosoma cruzi amastigotes growing in cell-free medium. J Protozool. 1989 Jan-Feb; 36(1):14-20.
    View in: PubMed
  135. Madoff S, Hooper DC. Nongenitourinary infections caused by Mycoplasma hominis in adults. Rev Infect Dis. 1988 May-Jun; 10(3):602-13.
    View in: PubMed
  136. Wolfson JS, Hooper DC. Norfloxacin: a new targeted fluoroquinolone antimicrobial agent. Ann Intern Med. 1988 Feb; 108(2):238-51.
    View in: PubMed
  137. Hooper DC, Wolfson JS. Mode of action of the quinolone antimicrobial agents. Rev Infect Dis. 1988 Jan-Feb; 10 Suppl 1:S14-21.
    View in: PubMed
  138. Wolfson JS, Hooper DC, Ng EY, Souza KS, McHugh GL, Swartz MN. Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers. Antimicrob Agents Chemother. 1987 Nov; 31(11):1861-3.
    View in: PubMed
  139. Wolfson JS, McHugh GL, Swartz MN, Ng EY, Hooper DC. Visualization of the mitochondrion-kinetoplast in viable Trypanosoma cruzi with rhodamine 123. J Parasitol. 1987 Aug; 73(4):866-9.
    View in: PubMed
  140. Hooper DC, Wolfson JS, Ng EY, Swartz MN. Mechanisms of action of and resistance to ciprofloxacin. Am J Med. 1987 Apr 27; 82(4A):12-20.
    View in: PubMed
  141. Hooper DC, Wolfson JS, Souza KS, Tung C, McHugh GL, Swartz MN. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother. 1986 Apr; 29(4):639-44.
    View in: PubMed
  142. Wolfson JS, McHugh GL, Hooper DC, Swartz MN. Knotting of DNA molecules isolated from deletion mutants of intact bacteriophage P4. Nucleic Acids Res. 1985 Sep 25; 13(18):6695-702.
    View in: PubMed
  143. Weber DJ, Wolfson JS, Swartz MN, Hooper DC. Pasteurella multocida infections. Report of 34 cases and review of the literature. Medicine (Baltimore). 1984 May; 63(3):133-54.
    View in: PubMed
  144. Hooper DC, Wolfson JS, McHugh GL, Swartz MD, Tung C, Swartz MN. Elimination of plasmid pMG110 from Escherichia coli by novobiocin and other inhibitors of DNA gyrase. Antimicrob Agents Chemother. 1984 May; 25(5):586-90.
    View in: PubMed
  145. Wolfson JS, Hooper DC, Swartz MN, Swartz MD, McHugh GL. Novobiocin-induced elimination of F'lac and mini-F plasmids from Escherichia coli. J Bacteriol. 1983 Dec; 156(3):1165-70.
    View in: PubMed
  146. Hooper DC, Bayer AS, Karchmer AW, Theofilopoulos AN, Swartz MN. Circulating immune complexes in prosthetic valve endocarditis. Arch Intern Med. 1983 Nov; 143(11):2081-4.
    View in: PubMed
  147. Wolfson JS, Hooper DC, Swartz MN, Swartz MD, McHugh GL. Rapid method for screening large numbers of Escherichia coli colonies for production of plasmid-mediated beta-lactamases. Antimicrob Agents Chemother. 1983 Feb; 23(2):308-12.
    View in: PubMed
  148. Hooper DC, Wolfson JS, McHugh GL, Winters MB, Swartz MN. Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrob Agents Chemother. 1982 Oct; 22(4):662-71.
    View in: PubMed
  149. Wolfson JS, Hooper DC, Swartz MN, McHugh GL. Antagonism of the B subunit of DNA gyrase eliminates plasmids pBR322 and pMG110 from Escherichia coli. J Bacteriol. 1982 Oct; 152(1):338-44.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Hooper's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (449) concept(s)
_
Co-Authors
See all (41) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_